Neurology Central

Latest erenumab trial signals hope for refractory migraine sufferers

Amgen (CA, USA) has announced finding from its latest trial investigating the drug Aimovig™ (erenumab) for the treatment of episodic migraines in patients who have not responded to previous treatment.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.